Conflicted interests: obesity drugs, alcohol, clinical trials
Food Politics
DECEMBER 11, 2023
DRUGS Here’s the headline: Maker of Wegovy, Ozempic showers money on U.S. obesity doctors Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found. It concentrated that money on an elite group of obesity specialists who advocate giving its powerful and expensive drugs to tens of millions of Americans.
Let's personalize your content